Ishikawa Xenograft Model Service for Endometrial Cancer

The Ishikawa xenograft model represents a well-characterized, hormone-responsive platform for evaluating endometrial cancer therapeutics in vivo. Alfa Cytology delivers validated Ishikawa xenograft services with integrated endpoint analysis to accelerate your preclinical development pipeline.

Overview of Ishikawa Xenograft Model for Endometrial Cancer

The Ishikawa cell line was originally established from a well-differentiated endometrial adenocarcinoma (grade 1) resected from a 39-year-old Japanese patient. It retains epithelial morphology, forms glandular structures in culture, and expresses functional estrogen and progesterone receptors, making it a representative model for hormone-dependent endometrial cancer biology. In xenograft settings, Ishikawa tumors grow reliably in immunodeficient mice and maintain receptor expression profiles that allow investigators to study hormone-regulated tumor progression, endocrine resistance, and targeted therapy response.

As a type I endometrial cancer model, the Ishikawa xenograft recapitulates key molecular features of endometrioid adenocarcinoma, including PI3K/AKT/mTOR pathway activation, MAPK signaling, and Wnt/beta-catenin dysregulation. The model has been extensively utilized to assess hormonal agents, chemotherapeutics, ferroptosis inducers, and novel small molecules, providing reproducible tumor growth kinetics and endpoint data for pharmacodynamic and efficacy studies.

Figure 1. The lobaplatin inhibited proliferation and arrested cell cycle progression in human endometrial carcinoma cell line. (He, Jingchao, et al., 2019)

Cell Line Information: Ishikawa

The Ishikawa cell line is a well-established endometrial adenocarcinoma model with the following characteristics:

Our Services

Alfa Cytology offers a fully validated Ishikawa xenograft model service tailored to preclinical endometrial cancer drug development. Our platform includes cell line authentication, optimized inoculation protocols, randomized group assignment, and comprehensive endpoint collection---including tumor volume monitoring, body weight tracking, histopathology, immunohistochemistry, and biomarker analysis---to deliver reproducible, audit-ready data packages for your IND-enabling studies.

Workflow of Ishikawa Xenograft Model Construction

Our Ishikawa xenograft construction workflow follows a standardized, quality-controlled process from cell preparation to endpoint analysis. Each stage is designed to ensure tumor take rates, growth consistency, and data integrity across study cohorts.

1. Cell Preparation & Quality Control: Ishikawa cells are expanded under standard culture conditions, authenticated by STR profiling, and confirmed for mycoplasma negativity. Cells are harvested at logarithmic growth phase, washed, and resuspended in serum-free medium mixed with Matrigel at a defined ratio to enhance engraftment.
2. Animal Preparation & Ethical Review: Immunodeficient mice (BALB/c nude or NOD/SCID) are acclimated for one week. All procedures are conducted under approved IACUC protocols with humane endpoints predefined.
3. Tumor Inoculation: A cell suspension (typically 1 x 10^6 to 5 x 10^6 cells in 100-200 microL) is injected subcutaneously into the flank region using a sterile insulin syringe. Alternatively, orthotopic uterine body injection may be performed for site-specific studies.
4. Tumor Monitoring & Randomization: Tumors are palpated twice weekly. Once tumors reach 50-100 mm^3, animals are randomized into treatment and vehicle groups based on tumor volume and body weight to minimize inter-group variability.
5. Treatment Administration: Test compounds are administered via the route specified in the study design (oral gavage, intraperitoneal, or intravenous). Dosing schedules and formulations are documented in the study protocol.
6. Endpoint Collection & Analysis: At study termination, tumors are excised, weighed, and photographed. Blood is collected for clinical chemistry and pharmacokinetic analysis. Tumor tissue is processed for H&E staining, IHC (Ki-67, cleaved caspase-3, ER/PR status), and molecular profiling (Western blot, qPCR, or RNA-seq).

Figure 2: Schematic workflow illustrating the derivation and construction of the Ishikawa Xenograft Model at Alfa Cytology.

Case Study-Ishikawa Xenograft Model Development

In a representative preclinical study, Ishikawa cells were engrafted subcutaneously into female BALB/c nude mice to evaluate candidate therapeutic efficacy. Tumors established within 10-14 days post-inoculation and exhibited consistent exponential growth. Treatment arms received a novel targeted agent or vehicle control according to the study design. Tumor growth inhibition, biomarker modulation, and tolerability endpoints were captured throughout the study duration, yielding a robust dataset suitable for downstream pharmacodynamic interpretation and regulatory documentation. Specific quantitative results can be customized to align with client compound profiles upon request.

Why Choose Alfa Cytology?

Alfa Cytology provides a scientifically rigorous, compliance-driven environment for endometrial cancer xenograft studies. Our team integrates cell biology expertise with in vivo pharmacology to deliver actionable preclinical insights.

• Validated Ishikawa cell stock with confirmed STR identity and hormone receptor expression profile.
• Standardized xenograft protocols with high tumor take rates and reproducible growth kinetics.
• Comprehensive endpoint menu including tumor imaging, histopathology, IHC, and molecular biomarker analysis.
• Flexible study designs accommodating monotherapy, combination therapy, and endocrine resistance models.
• GLP-compliant data collection and reporting to support IND submission and regulatory filings.

Contact Us

Ready to advance your endometrial cancer pipeline with a validated Ishikawa xenograft model? Contact us today to discuss your study objectives, and our team will design a customized preclinical program aligned with your development milestones. Reach out to us now to receive a detailed proposal and timeline.

For research use only. Not intended for any clinical use.